Cystic Fibrosis (CF) Therapeutics Market By Therapeutics (Mucolytics, Bronchodilators, CFTR modulators, Pancreatic enzyme supplements), By Route of Administration (Inhaled drugs, Oral drugs), Industry Trends, Estimation & Forecast, 2017 - 2025

Check Today's Best Price

$3500 Buy Now
Cystic fibrosis therapeutics market is expected to grow with a CAGR of 16.2% during the forecast period of 2018 to 2025.
  • Market Overview:

    Cystic fibrosis is a chronic, progressive disease causing severe damage to the exocrine glands of body such as pancreas, liver, lungs, and intestines. It is caused by mutation in the gene Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that alters the normal fluid and electrolyte secretion function of the secretory glands. The surging occurrence of cystic fibrosis is the major factor involved in the growth of the cystic fibrosis therapeutics market. Based on the data revealed by the Cystic Fibrosis Research Inc., more than 30,000 people in the United States have cystic fibrosis and approximately 900-1000 new cases of fatal CF arise every year. Various initiatives are being taken by the non-profit organizations and government, which is also contributing towards the market growth of cystic fibrosis therapeutics.

    The commencement of beneficial programs for patients suffering from cystic fibrosis has stimulated the demand for cystic fibrosis therapeutics. For example, in 2017, a neonatal screening program for cystic fibrosis had covered most of the Brazilian states, with referral centers kept for the patient’s follow up. The high cost of the treatment procedures, unfavourable reimbursement scenario, and huge R&D investments are creating hurdles in the market growth. In the current scenario, there is no permanent cure for cystic fibrosis, however, advancements in technology has led to the advent of gene therapy, which is anticipated to change the scenario in the near future.

    The report provides detailed qualitative and quantitative analysis of the cystic fibrosis therapeutics market. Market size and forecast has been provided for the period – (2018 – 2025), for the segments namely therapeutics and route of administration in each of the major regions.

    Cystic Fibrosis Therapeutics Market Segmentation

    By Therapeutics
    •    Mucolytics
    •    Bronchodilators
    •    CFTR modulators
    •    Pancreatic enzyme supplements

    By Route of Administration
    •    Inhaled drugs
    •    Oral drugs

    By Geography

    •    North America
    o    U.S.
    o    Canada
    o    Mexico

    •    Europe
    o    U.K.
    o    France
    o    Germany
    o    Italy
    o    Spain
    o    Rest of Europe

    •    Asia-Pacific
    o    China
    o    Japan
    o    India
    o    Korea
    o    Rest of APAC

    •    South America
    o    Brazil
    o    Rest of South America

    •    Rest of the World
    o    Middle East
    o    Africa

    keyboard_arrow_up
  • CHAPTER 1.    INTRODUCTION
    1.1.    RESEARCH METHODOLOGY
    1.1.1.    ERC desk research
    1.1.2.    ERC data synthesis
    1.1.3.    Data validation and market feedback
    1.1.4.    ERC data sources
    CHAPTER 2.    CYSTIC FIBROSIS THERAPEUTICS MARKET OVERVIEW
    2.1.    CYSTIC FIBROSIS THERAPEUTICS MARKET INTRODUCTION
    2.2.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE AND GROWTH RATE, 2017-2025
    2.2.1.    Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
    CHAPTER 3.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET BY THERAPEUTICS, 2017-2025
    3.1.    MUCOLYTICS
    3.2.    BRONCHODILATORS
    3.3.    CFTR MODULATORS
    3.4.    PANCREATIC ENZYME SUPPLEMENTS
    3.5.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE BY THERAPEUTICS, 2017-2025
    3.5.1.    Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Share (%) By Therapeutics, 2017-2025
    3.5.2.    Mucolytics Market Revenue and Growth Rate, 2017-2025
    3.5.3.    Bronchodilators Market Revenue and Growth Rate, 2017-2025
    3.5.4.    CFTR modulators Market Revenue and Growth Rate, 2017-2025
    CHAPTER 4.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION, 2017-2025
    4.1.    INHALED DRUGS
    4.2.    ORAL DRUGS
    4.3.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE BY ROUTE OF ADMINISTRATION, 2017-2025
    4.3.1.    Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Share (%) By Route of Administration, 2017-2025
    4.3.2.    Inhaled drugs Market Revenue and Growth Rate, 2017-2025
    4.3.3.    Oral drugs Market Revenue and Growth Rate, 2017-2025
    CHAPTER 5.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET BY REGION, 2017-2025
    5.1.    NORTH AMERICA
    5.1.1.    U.S.
    5.1.2.    Canada
    5.1.3.    Mexico
    5.2.    EUROPE
    5.2.1.    U.K.
    5.2.2.    France
    5.2.3.    Germany
    5.2.4.    Italy
    5.2.5.    Spain
    5.2.6.    Rest of Europe
    5.3.    ASIA PACIFIC
    5.3.1.    China
    5.3.2.    Japan
    5.3.3.    India
    5.3.4.    Korea
    5.3.5.    Rest of APAC
    5.4.    SOUTH AMERICA
    5.4.1.    Brazil
    5.4.2.    Rest of South America
    5.5.    REST OF THE WORLD
    5.5.1.    Middle East
    5.5.2.    Africa
    5.6.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE BY REGION, 2017-2025
    5.6.1.    Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Share (%) By Region, 2017-2025
    5.6.2.    North America Market Revenue and Growth Rate, 2017-2025
    5.6.3.    Europe Market Revenue and Growth Rate, 2017-2025
    5.6.4.    Asia Pacific Market Revenue and Growth Rate, 2017-2025
    5.6.5.    South America Market Revenue and Growth Rate, 2017-2025
    5.6.6.    Rest of the World Market Revenue and Growth Rate, 2017-2025
    CHAPTER 6.    VALUE CHAIN ANALYSIS
    CHAPTER 7.    MARKET DETERMINANTS
    7.1.    MARKET DRIVERS
    7.2.    MARKET RESTRAINTS
    7.3.    MARKET OPPORTUNITIES
    7.4.    MARKET DETERMINANTS RADAR CHART
    CHAPTER 8.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET COMPETITION BY MANUFACTURERS
    8.1.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
    CHAPTER 9.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MANUFACTURERS ANALYSIS
    9.1.    ABBVIE INC.
    9.1.1.    Business Overview
    9.1.2.    Company Basic Information
    9.1.3.    Cystic Fibrosis Therapeutics Product Details
    9.1.4.    AbbVie Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.2.    NOVARTIS AG
    9.2.1.    Business Overview
    9.2.2.    Company Basic Information
    9.2.3.    Cystic Fibrosis Therapeutics Product Details
    9.2.4.    Novartis AG Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.3.    TEVA PHARMACEUTICAL INDUSTRIES LTD
    9.3.1.    Business Overview
    9.3.2.    Company Basic Information
    9.3.3.    Cystic Fibrosis Therapeutics Product Details
    9.3.4.    Teva Pharmaceutical Industries Ltd. Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.4.    MERCK & CO. INC.
    9.4.1.    Business Overview
    9.4.2.    Company Basic Information
    9.4.3.    Cystic Fibrosis Therapeutics Product Details
    9.4.4.    Merck & Co. Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.5.    ALCRESTA THERAPEUTICS INC.
    9.5.1.    Business Overview
    9.5.2.    Company Basic Information
    9.5.3.    Cystic Fibrosis Therapeutics Product Details
    9.5.4.    Alcresta Therapeutics Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.6.    ALLERGAN PLC
    9.6.1.    Business Overview
    9.6.2.    Company Basic Information
    9.6.3.    Cystic Fibrosis Therapeutics Product Details
    9.6.4.    Allergan Plc Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.7.    F. HOFFMANN-LA ROCHE LTD.
    9.7.1.    Business Overview
    9.7.2.    Company Basic Information
    9.7.3.    Cystic Fibrosis Therapeutics Product Details
    9.7.4.    F. Hoffmann-La Roche Ltd. Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.8.    GILEAD SCIENCES, INC.
    9.8.1.    Business Overview
    9.8.2.    Company Basic Information
    9.8.3.    Cystic Fibrosis Therapeutics Product Details
    9.8.4.    Gilead Sciences, Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.9.    ASTRAZENECA PLC
    9.9.1.    Business Overview
    9.9.2.    Company Basic Information
    9.9.3.    Cystic Fibrosis Therapeutics Product Details
    9.9.4.    AstraZeneca Plc Cystic Fibrosis Therapeutics Revenue and Gross Margin
    9.10.    ALAXIA
    9.10.1.    Business Overview
    9.10.2.    Company Basic Information
    9.10.3.    Cystic Fibrosis Therapeutics Product Details
    9.10.4.    Alaxia  Cystic Fibrosis Therapeutics Revenue and Gross Margin

    keyboard_arrow_up
  • •    AbbVie Inc.
    •    Novartis AG
    •    Teva Pharmaceutical Industries Ltd.
    •    Merck & Co. Inc.
    •    Alcresta Therapeutics Inc.
    •    Allergan Plc
    •    F. Hoffmann-La Roche Ltd.
    •    Gilead Sciences, Inc.
    •    AstraZeneca Plc
    •    Alaxia
    •    Vertex Pharmaceuticals Inc.

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Cystic Fibrosis Therapeutics Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Cystic Fibrosis Therapeutics Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

CLIENTS

SHARE YOUR CART